Marianne De Backer, Vir Biotechnology CEO
June 5, 2024 05:57 AM EDTUpdated 09:48 AM
R&D

Vir's ear­ly Phase 2 he­pati­tis D da­ta show re­duc­tion, re­moval of virus with com­bo and monother­a­py

Katherine Lewin

News Reporter

Vir’s chron­ic he­pati­tis D treat­ment re­duced the pres­ence of the virus RNA as well as nor­mal­ized cer­tain liv­er en­zyme lev­els across 24 weeks in a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Why the Supreme Court's over­rule of Chevron has ma­jor im­pli­ca­tions for the FDA

J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

FDA re­jects Rock­et Phar­ma’s ul­tra-rare im­mune dis­ease gene ther­a­py over man­u­fac­tur­ing

Supreme Court nar­row­ly re­jects Pur­due bank­rupt­cy plan, says it gives Sack­lers too much pro­tec­tion

GSK’s man­u­fac­tur­ing sites in Sin­ga­pore will use 100% re­new­able en­er­gy by 2025 

In­side BAR­DA's multi­bil­lion-dol­lar ef­fort to fund long-shot biotechs for Covid

A service from the Financial Times